Catalyst Wire Dossier Catalyst Wire Dossier

Influenza vaccine MF59C.1-adjuvanted (Vaccine B)

Influenza vaccine MF59C.1-adjuvanted · Novartis
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Influenza vaccine MF59C.1-adjuvanted (Vaccine B), covering 2007-03-13 to 2007-03-13. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects [Phase 2]

See pricing